The well-posedness of the stochastic nonlinear Schr\"odinger equations in H2(Rd)H^2(\mathbb{R}^d)

The Cauchy problem for the stochastic nonlinear Schr\"odinger equation with a multiplicable noise is considered where the nonlinear term is of a power type and its coefficients are complex numbers. In particular, it is extremely important to consider the complex coefficients in the noise which cover non-conservative case, because they include measurement effects in quantum physics. The main purpose of this paper is to construct classical solutions in $H^2(\mathbb{R}^d)$ for the problem in question. The time local well-posedness in $L^2(\mathbb{R}^d)$ and $H^1(\mathbb{R}^d)$ was investigated in the papers [7,8]. In this paper we study the well-posedness in $H^2(\mathbb{R}^d)$ by making use of the rescaling approach as a main tool for dealing with the multiple noise, where we need to take advantage of a slight modification of the deterministic Strichartz estimate to fit into requirements under the setting of $H^2(\mathbb{R}^d)$. The other difficulty lies on the discussion on smoothness of functions in the nonlinear term, where the proof of time local well-posedness for the case of $H^2$-solutions does not go similarly as in the cases of $L^2$-solutions or $H^1$-solutions, because of the complexity in the computation of the nonlinear term with lower exponent $\alpha$. The techniques of Kato [18,19] work well on this difficulty even for the stochastic equations. We use the stochastic Strichartz estimate [4,16,17] as well to deal with white noise which did not appear in the proof for $L^2$-solutions or $H^1$-solutions. We also discuss time-global solutions in $H^2(\mathbb{R}^d)$.Comment: 31 pages, no figures. arXiv admin note: text overlap with arXiv:1404.5039 by other author

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors. Methods Sunitinib was administered once daily on a continuous daily dosing (CDD) schedule (37.5 mg/day) or a 2-weeks-on, 1-week-off treatment schedule (50 mg/day, Schedule 2/1) in combination with pemetrexed at 500 mg/m2 on day 1 of repeated 21-day cycles. Results Twelve patients were enrolled in the study: six on the CDD schedule and six on Schedule 2/1. None of the treated patients experienced a dose-limiting toxicity. Toxicities were manageable and similar in type to those observed in monotherapy studies of sunitinib and pemetrexed. Pharmacokinetic analysis did not reveal any substantial drug–drug interaction. One patient with squamous cell lung cancer showed a partial response and five patients had stable disease. Conclusions Combination therapy with sunitinib administered on Schedule 2/1 (50 mg/day) or a CDD schedule (37.5 mg/day) together with standard-dose pemetrexed (500 mg/m2) was well tolerated in previously treated patients with advanced solid tumors

Buffer-gas pressure broadening for the (0 00 3) ← (0 00 0) band of N2O measured with continuous-wave cavity ring-down spectroscopy

Buffer-gas pressure broadening for the (0 00 3) ← (0 00 0) band of N2O was investigated with continuous-wave cavity ring-down spectroscopy within the temperature range of 243–353 K. The measured absorption profiles were analyzed with Voigt functions. The pressure broadening coefficients, γ(gas), and the temperature dependent parameters (broadening exponent) were determined for a variety of buffer gases: N2, O2, He, Ne, Ar, Kr, and Xe. γ(air) values were also determined using γ(N2) and γ(O2). The effective potential well depth for (N2O)2 under room temperature was estimated from γ(Ne, Ar, Kr, Xe) using the Permenter–Seaver’s model, and the results were compared with theoretical calculations. Simultaneously, the effective potential well depth for (CO2)2 is discussed.PublishedTomoki Nakayama, Hisato Fukuda, Akihiro Sugita, Satoshi Hashimoto, Masahiro Kawasaki, Simone Aloisio, Isamu Morino, Gen Inoue, Buffer-gas pressure broadening for the (0 00 3) <-- (0 00 0) band of N2O measured with continuous-wave cavity ring-down spectroscopy, Chemical Physics, Volume 334, Issues 1-3, 20 April 2007, Pages 196-203.https://doi.org/10.1016/j.chemphys.2007.03.0010301-010

Disentangling the 1MLCT transition of [Ru(bpy)3]2+ by Stark absorption spectroscopy

金沢大学理工研究域物質化学系The metal-to-ligand charge transfer (MLCT) transition of [Ru(bpy)3]2+ was investigated using Stark absorption spectroscopy, where bpy is the abbreviation of 2,2\u27-bipyridyl ligand. The magnitude and direction of the photoinduced intramolecular charge transfer were precisely determined for the 1MLCT transition of [Ru(bpy)3]2+. The 1MLCT absorption band of [Ru(bpy)3]2+, observed in the 18,000-30,000cm-1 spectral region, is composed of several sub-bands that can be approximated with Gaussian profiles. In particular, three distinct major 1MLCT bands of [Ru(bpy)3]2+ (g4, 21272cm-1; g5, 22026cm-1; g7, 23448cm-1) could be distinguished by the direction of the charge transfer of each transition. The experimentally determined directions of charge transfer showed good agreement with the theoretical prediction by Kober and Meyer. We also re-examined the phosphorescence and the excitation spectra of [Ru(bpy)3]2+. The 1MLCT excited states of the g5 and g7 bands almost completely transform to 3MLCT excited states, and then 40% of the 3MLCT state relaxes to the ground state by emitting phosphorescence. 46% of 1MLCT excited state of the g4 band non-radiatively relaxes to the ground state. These results provide good support for the assignment of the different origins of the g4 and other two Gaussian sub-bands (g5 and g7). © 2017 Elsevier B.V.in Press / Embargo Period 12 month

The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

「コロナ制圧タスクフォース」COVID-19患者由来の血液細胞における遺伝子発現の網羅的解析 --重症度に応じた遺伝子発現の変化には、ヒトゲノム配列の個人差が影響する--. 京都大学プレスリリース. 2022-08-23.Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection

DOCK2 is involved in the host genetics and biology of severe COVID-19

「コロナ制圧タスクフォース」COVID-19疾患感受性遺伝子DOCK2の重症化機序を解明 --アジア最大のバイオレポジトリーでCOVID-19の治療標的を発見--. 京都大学プレスリリース. 2022-08-10.Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge. Here we conducted a genome-wide association study (GWAS) involving 2, 393 cases of COVID-19 in a cohort of Japanese individuals collected during the initial waves of the pandemic, with 3, 289 unaffected controls. We identified a variant on chromosome 5 at 5q35 (rs60200309-A), close to the dedicator of cytokinesis 2 gene (DOCK2), which was associated with severe COVID-19 in patients less than 65 years of age. This risk allele was prevalent in East Asian individuals but rare in Europeans, highlighting the value of genome-wide association studies in non-European populations. RNA-sequencing analysis of 473 bulk peripheral blood samples identified decreased expression of DOCK2 associated with the risk allele in these younger patients. DOCK2 expression was suppressed in patients with severe cases of COVID-19. Single-cell RNA-sequencing analysis (n = 61 individuals) identified cell-type-specific downregulation of DOCK2 and a COVID-19-specific decreasing effect of the risk allele on DOCK2 expression in non-classical monocytes. Immunohistochemistry of lung specimens from patients with severe COVID-19 pneumonia showed suppressed DOCK2 expression. Moreover, inhibition of DOCK2 function with CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection, characterized by weight loss, lung oedema, enhanced viral loads, impaired macrophage recruitment and dysregulated type I interferon responses. We conclude that DOCK2 has an important role in the host immune response to SARS-CoV-2 infection and the development of severe COVID-19, and could be further explored as a potential biomarker and/or therapeutic target